A novel therapy called CBP501 is the feature of a recent clinical trial for mesothelioma.
When paired with chemotherapy drugs cisplatin and pemetrexed, CBP501 increases the chances of progression-free survival after four months.
The study began in 2008, when it was first posted on the clinicaltrials.gov website database. It posted the phase 1/2 results in July of 2021.
There were 69 patients enrolled. Six were in phase 1, which determined the proper dose for CBP501 with mesothelioma chemotherapy. The other 63 were put in a dual-cohort phase 2 study: 40 receiving CBP501 plus chemotherapy, and 23 receiving just chemotherapy.
The main assessment was progression-free survival after four months. Between 63% and 68% of the patients receiving CBP501 reached this milestone. Only 39-56% of chemotherapy-only patients hit this mark.
What Is CBP501?
CBP501 is an injectable peptide also serving as a checkpoint inhibitor for G2. This drug prevents division of damaged cells – instead allowing time for repair.
Patients received 20mg of CBP501, which includes a peptide acetate salt. Patients received this drug, plus chemotherapy, once every three weeks. This falls in line with the usual chemotherapy “cycles” occurring every three weeks.
Health Concerns With CBP501?
Only one patient in each cohort died during the study. Around the same percentage of patients experienced serious side effects from treatment:
- 52% in the CBP501 group
- 56% in the chemotherapy-only group
The most common side effects from CBP501 were similar to those linked to chemotherapy:
This information implies there is no added health concern from CBP501 compared to systemic chemotherapy.
The clinical trial was held at various United States cancer centers, including:
If you wish to enroll in a clinical trial for mesothelioma, let us know. Our registered nurse, Karen Ritter, is a dedicated patient advocate aiming to help patients and families. Email her at firstname.lastname@example.org for assistance or guidance in fighting this cancer.
Sources & Author
- Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II). Clinicaltrials.gov. Retrieved from: https://clinicaltrials.gov/ct2/show/study/NCT00700336. Accessed: 01/12/2021.
- serine/threonine kinase inhibitor CBP501. National Cancer Institute. Retrieved from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/serine-threonine-kinase-inhibitor-cbp501. Accessed: 01/12/2021.
Sources & Author